Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Baloxavir marboxil - Roche/Shionogi

Drug Profile

Baloxavir marboxil - Roche/Shionogi

Alternative Names: RG 6152; RG 6152-1; S 033188; XOFLUZA; Xofluza

Latest Information Update: 06 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Developer Roche; Shionogi
  • Class Antivirals; Dibenzothiepins; Esters; Morpholines; Pyridines; Small molecules; Triazines
  • Mechanism of Action Endonuclease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza A virus infections; Influenza B virus infections; Influenza virus infections
  • No development reported Influenza A virus H5N1 subtype

Most Recent Events

  • 10 May 2024 Roche completes a phase III trial in Influenza virus infections (In adolescents, In children, In adults) in Bulgaria, China, Hungary, New Zealand, Puerto Rico, the US, Argentina, Costa Rica, Greece, Hong Kong, India, Israel, Japan, Mexico, Poland, South Africa, Singapore, Spain, Turkey, the UK (PO) (NCT03969212) (EudraCT2018-004056-37)
  • 15 Feb 2024 Roche plans regulatory filing for Influenza virus infection (direct transmission) in 2024 (Roche pipeline, February 2024)
  • 15 Nov 2023 Hoffmann-La Roche initiates a phase IIIb Pebblestone trial in Influenza (In children) in USA (PO) (NCT06094010)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top